Very well written. I'm also considering Sartorius right now. The biggest worry is management incinerating capital with m&a after many perceived polyplus to be expensive. Track record over the years is good though. Long term trends are in tact and right now everything in the TTM numbers look negative.
Admittedly, the Polyplus deal seems quite expensive though some analysts suggest that half of the CGT pipelines could potentially utilize it. I think the company is aiming to strengthen its market position in the upstream sector. Polyplus in the CGT modality and its attempt to acquire Maravi for mRNA modality in the past. Though both deals are quite expensive...
Very well written. I'm also considering Sartorius right now. The biggest worry is management incinerating capital with m&a after many perceived polyplus to be expensive. Track record over the years is good though. Long term trends are in tact and right now everything in the TTM numbers look negative.
Admittedly, the Polyplus deal seems quite expensive though some analysts suggest that half of the CGT pipelines could potentially utilize it. I think the company is aiming to strengthen its market position in the upstream sector. Polyplus in the CGT modality and its attempt to acquire Maravi for mRNA modality in the past. Though both deals are quite expensive...